Anti-Tumor Necrosis Factor-α Monotherapy Versus Combination Therapy with an Immunomodulator in IBD

Parambir S. Dulai; Corey A. Siegel; Laurent Peyrin-Biroulet

doi:10.1016/j.gtc.2014.05.009

Anti-Tumor Necrosis Factor-α Monotherapy Versus Combination Therapy with an Immunomodulator in IBD

Parambir S. Dulai, Corey A. Siegel, Laurent Peyrin-Biroulet^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

16 Scopus citations

Abstract

Inflammatory bowel disease (IBD) treatment has progressed significantly over the past decade with the advent of biologics. Anti-tumor necrosis factor (anti-TNF) agents are the most widely available biologics, but the optimal approach when using them remains unclear. In this review, we highlight the currently available evidence regarding the use of anti-TNF monotherapy versus combination therapy with an immunomodulator. We focus on those patients at greatest risk for adverse events and outline the clinical approach when considering the use of combination therapy. We review the available tools through which providers may efficiently communicate these data to patients in the clinical setting.

Original language	English (US)
Pages (from-to)	441-456
Number of pages	16
Journal	Gastroenterology Clinics of North America
Volume	43
Issue number	3
DOIs	https://doi.org/10.1016/j.gtc.2014.05.009
State	Published - Sep 2014
Externally published	Yes

Keywords

Anti-TNF
Combination therapy
Immunomodulator
Monotherapy

ASJC Scopus subject areas

Gastroenterology

Access to Document

10.1016/j.gtc.2014.05.009

Cite this

@article{9885279016b74500bc3b6de3e8f19ead,

title = "Anti-Tumor Necrosis Factor-α Monotherapy Versus Combination Therapy with an Immunomodulator in IBD",

abstract = "Inflammatory bowel disease (IBD) treatment has progressed significantly over the past decade with the advent of biologics. Anti-tumor necrosis factor (anti-TNF) agents are the most widely available biologics, but the optimal approach when using them remains unclear. In this review, we highlight the currently available evidence regarding the use of anti-TNF monotherapy versus combination therapy with an immunomodulator. We focus on those patients at greatest risk for adverse events and outline the clinical approach when considering the use of combination therapy. We review the available tools through which providers may efficiently communicate these data to patients in the clinical setting.",

keywords = "Anti-TNF, Combination therapy, Immunomodulator, Monotherapy",

author = "Dulai, {Parambir S.} and Siegel, {Corey A.} and Laurent Peyrin-Biroulet",

note = "Funding Information: Disclosures: C.A. Siegel serves on the advisory board and as a consultant for Abbvie, Janssen, Takeda and UCB, and has received grant support from AbbVie , Janssen , and UCB . He has delivered CME lectures for Abbvie, Janssen and Merck. Dr C.A. Siegel is supported by Grant number 1R01HS021747-01 from the Agency for Healthcare Research and Quality . ",

year = "2014",

month = sep,

doi = "10.1016/j.gtc.2014.05.009",

language = "English (US)",

volume = "43",

pages = "441--456",

journal = "Gastroenterology Clinics of North America",

issn = "0889-8553",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - Anti-Tumor Necrosis Factor-α Monotherapy Versus Combination Therapy with an Immunomodulator in IBD

AU - Dulai, Parambir S.

AU - Siegel, Corey A.

AU - Peyrin-Biroulet, Laurent

N1 - Funding Information: Disclosures: C.A. Siegel serves on the advisory board and as a consultant for Abbvie, Janssen, Takeda and UCB, and has received grant support from AbbVie , Janssen , and UCB . He has delivered CME lectures for Abbvie, Janssen and Merck. Dr C.A. Siegel is supported by Grant number 1R01HS021747-01 from the Agency for Healthcare Research and Quality .

PY - 2014/9

Y1 - 2014/9

N2 - Inflammatory bowel disease (IBD) treatment has progressed significantly over the past decade with the advent of biologics. Anti-tumor necrosis factor (anti-TNF) agents are the most widely available biologics, but the optimal approach when using them remains unclear. In this review, we highlight the currently available evidence regarding the use of anti-TNF monotherapy versus combination therapy with an immunomodulator. We focus on those patients at greatest risk for adverse events and outline the clinical approach when considering the use of combination therapy. We review the available tools through which providers may efficiently communicate these data to patients in the clinical setting.

AB - Inflammatory bowel disease (IBD) treatment has progressed significantly over the past decade with the advent of biologics. Anti-tumor necrosis factor (anti-TNF) agents are the most widely available biologics, but the optimal approach when using them remains unclear. In this review, we highlight the currently available evidence regarding the use of anti-TNF monotherapy versus combination therapy with an immunomodulator. We focus on those patients at greatest risk for adverse events and outline the clinical approach when considering the use of combination therapy. We review the available tools through which providers may efficiently communicate these data to patients in the clinical setting.

KW - Anti-TNF

KW - Combination therapy

KW - Immunomodulator

KW - Monotherapy

UR - http://www.scopus.com/inward/record.url?scp=84905750048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905750048&partnerID=8YFLogxK

U2 - 10.1016/j.gtc.2014.05.009

DO - 10.1016/j.gtc.2014.05.009

M3 - Review article

C2 - 25110252

AN - SCOPUS:84905750048

SN - 0889-8553

VL - 43

SP - 441

EP - 456

JO - Gastroenterology Clinics of North America

JF - Gastroenterology Clinics of North America

IS - 3

ER -

Anti-Tumor Necrosis Factor-α Monotherapy Versus Combination Therapy with an Immunomodulator in IBD

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this